Login Register Cart 0
Generic placeholder image

Current Rheumatology Reviews

Editor-in-Chief

ISSN (Print): 1573-3971
ISSN (Online): 1875-6360

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

COVID-19 Mortality in Patients with Rheumatic Diseases: A Real Concern

Author(s): Nasra K. Al-Adhoubi*, Maha Ali, Humaid Al Wahshi, Issa Al Salmi, Farida Al-Balushi, Talal Al Lawati, Abeer Mohammed, Ahmed Al Muqbali, Hilal Al Kalbani, Safiya Al-Abrawi and Faryal Khamis

Volume 18, Issue 3, 2022

Published on: 13 May, 2022

Page: [234 - 242] Pages: 9

DOI: 10.2174/1573397118666220412114514

Price: $65

Abstract

Background: Coronavirus disease 2019 (COVID 19) is a worldwide pandemic that has devastated the world in a way that has not been witnessed since the Spanish Flu in 1918. In this study, we aim to investigate the outcomes of patients with rheumatic diseases infected with COVID-19 in Oman.

Methods: A multi-center retrospective cohort study included patients with underlying rheumatological conditions and COVID-19 infection. Data were collected through the electronic record system and by interviewing the patients through a standard questionnaire.

Results: 113 patients with different rheumatic diseases were included with the following rheumatological diagnoses: rheumatoid arthritis (40.7%), systemic lupus erythematosus (23.1%), psoriatic arthritis (8%), Behcet's disease (7%), ankylosing spondylitis (6.2%), other vasculitides, including Kawasaki disease (4.4%), and other diagnoses (10.6%). The mean (SD) age of patients was 43 (14) years, and 82.3% were female. The diagnosis of COVID-19 was confirmed by PCR test in 84.1% of the patients.

The most common symptoms at the time of presentation were fever (86%), cough (81%), headache (65%), and myalgia (60%). Hospitalization due to COVID-19 infection was reported in 24.1% of the patients, and 52.2% of these patients had received some form of treatment.

In this cohort, the intake of immunosuppressive and immunomodulating medications was reported in 91.1% of the patients. During the COVID-19 infection, 68% of the patients continued taking their medications. Comorbidities were present in 39.8% of the patients. Pregnancy was reported in 2% of the patients. The 30 days mortality rate was found to be 3.5%. Diabetes, obesity, and interstitial lung diseases (ILD) were the strongest risk factor for mortality (p-value 0.000, 0.000, and 0.001, respectively). Rituximab was given in 3.8% of the patients, and it was significantly associated with increased mortality among the patients (p-value <0.001).

Conclusion: COVID-19 infection in patients with rheumatic diseases have an increased mortality rate in comparison to the general population, with diabetes, morbid obesity, chronic kidney diseases, interstitial lung disease, cardiovascular disease, obstructive lung disease, and liver diseases as comorbidities being the most severe risk factors associated with death. Greater care should be provided to this population, including the prompt need for vaccination.

Keywords: Rheumatic diseases, COVID-19, SARS-CoV-2, viral infection, autoimmune diseases, mortality, immunosuppressive therapy, comorbidities.

« Previous Next »
[1]
Pneumonia of unknown cause – China [Internet] World Health Organization 2021. https://www.who.int/csr/don/05-january-2020-pneumonia-of-unkown-cause-china/en/
[2]
WHO coronavirus disease (COVID-19) dashboard [Internet] Covid19whoint 2021. https://covid19.who.int
[3]
COVID-19 Vaccines [Internet]. U.S. Food and Drug Administration 2021.https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines#eua-vaccines
[4]
Haberman R, Axelrad J, Chen A, et al. Covid-19 in immune-mediated inflammatory diseases - case series from New York. N Engl J Med 2020; 383(1): 85-8.
[http://dx.doi.org/10.1056/NEJMc2009567] [PMID: 32348641]
[5]
Cordtz R, Lindhardsen J, Soussi B, et al. Incidence and severeness of COVID-19 hospitalisation in patients with inflammatory rheumatic disease: A nationwide cohort study from Denmark. Rheumatology 2021; 60(S1): S159-67.
[6]
Fredi M, Cavazzana I, Moschetti L, et al. COVID-19 in patients with rheumatic diseases in northern Italy: A single-centre observational and case-control study. Lancet Rheumatol 2020; 2(9): e549-56.
[http://dx.doi.org/10.1016/S2665-9913(20)30169-7] [PMID: 32838307]
[7]
Santos CS, Morales CM, Álvarez ED, Castro CÁ, Robles AL, Sandoval TP. Determinants of COVID-19 disease severity in patients with underlying rheumatic disease. Clin Rheumatol 2020; 39(9): 2789-96.
[http://dx.doi.org/10.1007/s10067-020-05301-2] [PMID: 32720259]
[8]
Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72314 cases from the Chinese center for disease control and prevention. JAMA 2020; 323(13): 1239-42.
[http://dx.doi.org/10.1001/jama.2020.2648] [PMID: 32091533]
[9]
Arshad S, Kilgore P, Chaudhry ZS, et al. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. Int J Infect Dis 2020; 97: 396-403.
[http://dx.doi.org/10.1016/j.ijid.2020.06.099] [PMID: 32623082]
[10]
Rosenberg ES, Dufort EM, Udo T, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state. JAMA 2020; 323(24): 2493-502.
[http://dx.doi.org/10.1001/jama.2020.8630] [PMID: 32392282]
[11]
Tomazini BM, Maia IS, Cavalcanti AB, et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: The codex randomized clinical trial. JAMA 2020; 324(13): 1307-16.
[http://dx.doi.org/10.1001/jama.2020.17021] [PMID: 32876695]
[12]
Gianfrancesco MA, Hyrich KL, Gossec L, et al. Rheumatic disease and COVID-19: Initial data from the COVID-19 Global Rheumatology Alliance provider registries. Lancet Rheumatol 2020; 2(5): e250-3.
[http://dx.doi.org/10.1016/S2665-9913(20)30095-3] [PMID: 32309814]
[13]
Hasseli R, Mueller-Ladner U, Schmeiser T, et al. National registry for patients with Inflammatory Rheumatic Diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): A valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD. RMD Open 2020; 6(2): e001332.
[http://dx.doi.org/10.1136/rmdopen-2020-001332] [PMID: 32878994]
[14]
Pablos JL, Galindo M, Carmona L, et al. Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: A multicentric matched cohort study. Ann Rheum Dis 2020; 79(12): 1544-9.
[http://dx.doi.org/10.1136/annrheumdis-2020-218296] [PMID: 32796045]
[15]
Loarce-Martos J, García-Fernández A, López-Gutiérrez F, et al. High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: A descriptive study. Rheumatol Int 2020; 40(12): 2015-21.
[http://dx.doi.org/10.1007/s00296-020-04699-x] [PMID: 32945944]
[16]
Mesas AE, Cavero-Redondo I, Álvarez-Bueno C, et al. Predictors of in-hospital COVID-19 mortality: A comprehensive systematic review and meta-analysis exploring differences by age, sex and health conditions. PLoS One 2020; 15(11): e0241742.
[http://dx.doi.org/10.1371/journal.pone.0241742] [PMID: 33141836]
[17]
Khamis F, Al Rashidi B, Al-Zakwani I, Al Wahaibi AH, Al Awaidy ST. Epidemiology of COVID-19 infection in Oman: Analysis of the first 1304 cases. Oman Med J 2020; 35(3): e145-5.
[http://dx.doi.org/10.5001/omj.2020.60] [PMID: 32647593]
[18]
Freites Nuñez DD, Leon L, Mucientes A, et al. Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2020; 79(11): 1393-9.
[http://dx.doi.org/10.1136/annrheumdis-2020-217984] [PMID: 32769150]
[19]
Khamis F, Memish Z, Bahrani MA, et al. Prevalence and predictors of in-hospital mortality of patients hospitalized with COVID-19 infection. J Infect Public Health 2021; 14(6): 759-65.
[http://dx.doi.org/10.1016/j.jiph.2021.03.016] [PMID: 34022734]
[20]
Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study. Lancet Respir Med 2020; 8(5): 475-81.
[http://dx.doi.org/10.1016/S2213-2600(20)30079-5] [PMID: 32105632]
[21]
Murray K, Quinn S, Turk M, et al. COVID-19 and rheumatic musculoskeletal disease patients: Infection rates, attitudes and medication adherence in an Irish population. Rheumatology 2021; 60(2): 902-6.
[PMID: 33164088]
[22]
Pistone A, Tant L, Soyfoo MS. Clinical course of COVID-19 infection in inflammatory rheumatological patients: A monocentric Belgian experience. Rheumatol Adv Pract 2020; 4(2): a055.
[http://dx.doi.org/10.1093/rap/rkaa055] [PMID: 33210075]
[23]
Fung M, Babik J. COVID-19 in immunocompromised hosts: What we know so far. Clin Infect Dis 2021; 72(2): 340-50.
[PMID: 33501974]
[24]
D’Silva KM, Serling-Boyd N, Wallwork R, et al. Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: A comparative cohort study from a US ‘hot spot’. Ann Rheum Dis 2020; 79(9): 1156-62.
[http://dx.doi.org/10.1136/annrheumdis-2020-217888] [PMID: 32457048]
[25]
Sanchez-Piedra C, Diaz-Torne C, Manero J, et al. Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies. Ann Rheum Dis 2020; 79(7): 988-90.
[http://dx.doi.org/10.1136/annrheumdis-2020-217948] [PMID: 32503857]
[26]
Sood A, Galestanian A, Murthy V, Gonzalez E, Raji M. COVID-19 infection among patients with rheumatic disease on biologic & targeted therapies: A systematic review. Arthritis Rheumatol 2020; 72(Suppl 10).
[27]
Favalli EG, Bugatti S, Klersy C, et al. Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis. Arthritis Res Ther 2020; 22(1): 290.
[http://dx.doi.org/10.1186/s13075-020-02395-6] [PMID: 33380344]
[28]
Emmi G, Bettiol A, Mattioli I, et al. SARS-CoV-2 infection among patients with systemic autoimmune diseases. Autoimmun Rev 2020; 19(7): 102575.
[http://dx.doi.org/10.1016/j.autrev.2020.102575] [PMID: 32376395]
[29]
Ferri C, Giuggioli D, Raimondo V, et al. COVID-19 and rheumatic autoimmune systemic diseases: Report of a large Italian patients series. Clin Rheumatol 2020; 39(11): 3195-204.
[http://dx.doi.org/10.1007/s10067-020-05334-7] [PMID: 32852623]
[30]
Kastritis E, Kitas GD, Vassilopoulos D, Giannopoulos G, Dimopoulos MA, Sfikakis PP. Systemic autoimmune diseases, anti-rheumatic therapies, COVID-19 infection risk and patient outcomes. Rheumatol Int 2020; 40(9): 1353-60.
[http://dx.doi.org/10.1007/s00296-020-04629-x] [PMID: 32654078]
[31]
Montero F, Martínez-Barrio J, Serrano-Benavente B, et al. Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: Clinical characteristics of poor outcomes. Rheumatol Int 2020; 40(10): 1593-8.
[http://dx.doi.org/10.1007/s00296-020-04676-4] [PMID: 32794113]
[32]
Nuño L, Novella Navarro M, Bonilla G, et al. Clinical course, severity and mortality in a cohort of patients with COVID-19 with rheumatic diseases. Ann Rheum Dis 2020; 79(12): 1659-61.
[http://dx.doi.org/10.1136/annrheumdis-2020-218054] [PMID: 32606046]
[33]
Xu C, Yi Z, Cai R, Chen R, Thong BY, Mu R. Clinical outcomes of COVID-19 in patients with rheumatic diseases: A systematic review and meta-analysis of global data. Autoimmun Rev 2021; 20(4): 102778.
[http://dx.doi.org/10.1016/j.autrev.2021.102778] [PMID: 33609804]
[34]
Mena-Vázquez N, Manrique Arija S, Rojas-Giménez M, et al. Hospitalization, and mortality from COVID-19 of patients with rheumatic inflammatory diseases in Andalusia. Reumatol Clin (Engl Ed) 2021; S1699-258X(21): 00089-99.
[35]
Conway R, Nikiphorou E, Demetriou CA, Low C, Leamy K, Ryan JG. COVID-19 global rheumatology alliance. Predictors of hospitalization in patients with rheumatic disease and COVID-19 in ireland: Data from the covid-19 global rheumatology alliance registry. Rheumatol Adv Pract 2021; 5(2): rkab031.
[36]
Ahmed S, Gasparyan AY, Zimba O. Comorbidities in rheumatic diseases need special consideration during the COVID-19 pandemic. Rheumatol Int 2021; 41(2): 243-56.
[http://dx.doi.org/10.1007/s00296-020-04764-5] [PMID: 33388969]
[37]
Onuora S. New data emerging on outcomes for patients with COVID-19 and rheumatic diseases. Nat Rev Rheumatol 2020; 16(8): 407.
[http://dx.doi.org/10.1038/s41584-020-0463-8] [PMID: 32620941]
[38]
Mikuls TR, Johnson SR, Fraenkel L, et al. American college of rheumatology guidance for the management of rheumatic disease in adult patients during the COVID-19 pandemic: Version 3. Arthritis Rheumatol 2021; 73(2): e1-e12.
[http://dx.doi.org/10.1002/art.41596] [PMID: 33277981]
[39]
Bakasis AD, Mavragani CP, Boki KA, et al. COVID-19 infection among autoimmune rheumatic disease patients: Data from an observational study and literature review. J Autoimmun 2021; 123: 102687.
[http://dx.doi.org/10.1016/j.jaut.2021.102687] [PMID: 34311142]
[40]
Wang Q, Liu J, Shao R, Han X, Su C, Lu W. Risk and clinical outcomes of COVID-19 in patients with rheumatic diseases compared with the general population: A systematic review and meta-analysis. Rheumatol Int 2021; 41(5): 851-61.
[http://dx.doi.org/10.1007/s00296-021-04803-9] [PMID: 33687528]
[41]
Belleudi V, Rosa AC, Poggi FR, et al. Direct and indirect impact of COVID-19 for patients with immune-mediated inflammatory diseases: A retrospective cohort study. J Clin Med 2021; 10(11): 2388.
[http://dx.doi.org/10.3390/jcm10112388] [PMID: 34071452]

Rights & Permissions Print Cite
Article Metrics
20
1
© 2024 Bentham Science Publishers | Privacy Policy